Regenerex Pharma Reports Increased Net Loss and Decreased Assets for Q2 2025

Regenerex Pharma, Inc. reported a significant increase in net loss for the three months ended June 30, 2025, amounting to $663,584, compared to a loss of $272,560 during the same period in 2024. The company's operating expenses rose sharply to $633,783 from $254,280, primarily driven by increased payroll and lease costs. The company continues to report no revenue, maintaining a trend from the previous fiscal year, which raises concerns about its financial sustainability.

The company's total assets decreased to $763,373 as of June 30, 2025, down from $1,263,236 at the end of the previous quarter. Current liabilities also saw a slight reduction, totaling $5,311,029 compared to $5,419,441 in March 2025. Regenerex's stockholders' deficit widened to $4,547,656, reflecting an accumulated deficit of $8,806,475. The company’s cash and equivalents dropped significantly to $172,430 from $653,025, indicating a pressing need for capital to support operations and product development.

Strategically, Regenerex has made notable moves, including the acquisition of proprietary wound healing technologies and the establishment of a partnership with Colltech Limited for ovine collagen products. This partnership aims to enhance Regenerex's product offerings in the wound care market, with a focus on regulatory approvals and distribution in the U.S. market. The company is also negotiating managed care agreements to provide its wound care products to Medicaid patients in southeastern states, which could potentially lead to significant cost savings for the healthcare system.

Operationally, Regenerex has not reported any customer counts or product adoption rates, as it has yet to generate revenue from its product lines. The company is in the process of launching its sales initiatives, with expectations to begin during the second quarter of the fiscal year ending March 31, 2026. The management has acknowledged the challenges in raising sufficient capital and achieving profitability, emphasizing the need for strategic financial planning to navigate its current financial landscape.

Looking ahead, Regenerex's management remains focused on securing additional capital to support its operations and product development. However, the company has expressed uncertainty regarding its ability to raise the necessary funds, which could impact its operational plans. The ongoing development of its wound care products and potential market entry strategies will be critical in determining the company's future financial performance and viability.